These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 12702566)

  • 1. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Dougherty TJ
    Lasers Surg Med; 2006 Jun; 38(5):439-44. PubMed ID: 16634075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.
    Bellnier DA; Greco WR; Nava H; Loewen GM; Oseroff AR; Dougherty TJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):40-5. PubMed ID: 16001178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
    Chan AL; Juarez M; Allen R; Volz W; Albertson T
    Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog.
    Payne JT; McCaw DL; Casteel SW; Frazier D; Rogers K; Tompson RV
    Lasers Surg Med; 1996; 18(4):406-9. PubMed ID: 8732580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization and treatment of transformed tissues using the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a.
    Furukawa K; Yamamoto H; Crean DH; Kato H; Mang TS
    Lasers Surg Med; 1996; 18(2):157-66. PubMed ID: 8833284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.
    Nava HR; Allamaneni SS; Dougherty TJ; Cooper MT; Tan W; Wilding G; Henderson BW
    Lasers Surg Med; 2011 Sep; 43(7):705-12. PubMed ID: 22057498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorophyll-a analogues conjugated with aminobenzyl-DTPA as potential bifunctional agents for magnetic resonance imaging and photodynamic therapy.
    Li G; Slansky A; Dobhal MP; Goswami LN; Graham A; Chen Y; Kanter P; Alberico RA; Spernyak J; Morgan J; Mazurchuk R; Oseroff A; Grossman Z; Pandey RK
    Bioconjug Chem; 2005; 16(1):32-42. PubMed ID: 15656573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer].
    Etienne J; Dorme N; Bourg-Heckly G; Raimbert P; Fékété F
    Bull Acad Natl Med; 2000; 184(8):1731-44; discussion 1744-7. PubMed ID: 11471391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
    Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non-Small Cell Carcinoma In Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study.
    Dhillon SS; Demmy TL; Yendamuri S; Loewen G; Nwogu C; Cooper M; Henderson BW
    J Thorac Oncol; 2016 Feb; 11(2):234-41. PubMed ID: 26718878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men.
    Triesscheijn M; Ruevekamp M; Out R; Van Berkel TJ; Schellens J; Baas P; Stewart FA
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):113-22. PubMed ID: 17009028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical compartmental pharmacokinetic modeling of 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) as a photosensitizer in rat plasma by validated HPLC method.
    Krishna KV; Saha RN; Puri A; Viard M; Shapiro BA; Dubey SK
    Photochem Photobiol Sci; 2019 May; 18(5):1056-1063. PubMed ID: 30608096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a.
    Bellnier DA; Henderson BW; Pandey RK; Potter WR; Dougherty TJ
    J Photochem Photobiol B; 1993 Sep; 20(1):55-61. PubMed ID: 8229470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
    Itkin A; Gilchrest BA
    Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat.
    Desroches MC; Bautista-Sanchez A; Lamotte C; Labeque B; Auchère D; Farinotti R; Maillard P; Grierson DS; Prognon P; Kasselouri A
    J Photochem Photobiol B; 2006 Oct; 85(1):56-64. PubMed ID: 16765603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesoscopic fluorescence tomography of a photosensitizer (HPPH) 3D biodistribution in skin cancer.
    Ozturk MS; Rohrbach D; Sunar U; Intes X
    Acad Radiol; 2014 Feb; 21(2):271-80. PubMed ID: 24439340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.